PDF icon Download PDF
Dtsch Med Wochenschr 2006; 131(41): 2279-2285
DOI: 10.1055/s-2006-951364
Übersicht | Review article
Rheumatologie
© Georg Thieme Verlag KG Stuttgart · New York

Biologika in der Therapie rheumatischer Erkrankungen

Biologicals in the treatment of rheumatic diseasesH. U. Scherer1 , G.-R Burmester1
  • 1Klinik für Rheumatologie und klinische Immunologie, Charité - Universitätsmedizin Berlin
Further Information

Publication History

eingereicht: 24.4.2006

akzeptiert: 14.9.2006

Publication Date:
11 October 2006 (online)

Also available ateRef
   Permissions and Reprints
Preview

Schlüsselwörter

Biologika - Therapestrategien - rheumatoide Arthritis - Vaskulitis - TNF-α-Antagonisten

Key words

biologics - therapeutic strategies - rheumatoid arthritis - vasculitis - TNF alfa antagonists

Literatur

  • 1 Anolik J, Campbell D, Felgar R, Rosenblatt J, Young F, Looney R J. B lymphocyte depletion in the treatment of systemic lupus (SLE): phase I/II trial of rituximab (Rituxan®) in SLE.  Arthritis Rheum. 2002;  (Suppl) 46 S46
    Search in Google Scholar
  • 2 Antoni C E, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester G R, Schneider U. et al . Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).  Arthritis Rheum. 2005;  52 1227-1236
    Search in Google Scholar
  • 3 Aries P M, Lamprecht P, Gross W L. Rituximab in refractory Wegener’s granulomatosis: favorable or not?.  Am J Respir Crit Care Med. 2006;  173 815-816
    Search in Google Scholar
  • 4 Askling J, Fored C M, Brandt L, Baecklund E, Bertilsson L, Feltelius N. et al . Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.  Ann Rheum Dis. 2005;  64 1421-1426
    Search in Google Scholar
  • 5 Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G. et al . Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.  Arthritis Res Ther. 2005;  7 R439-R444
    Search in Google Scholar
  • 6 Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis.  Arthritis Rheum. 2003;  48 1771-1774
    Search in Google Scholar
  • 7 Boers M, Verhoeven A C, Markusse H M, van de Laar M A, Westhovens R, van Denderen J C. et al . Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.  Lancet. 1997;  350 309-318
    Search in Google Scholar
  • 8 Bongartz T, Sutton A J, Sweeting M J, Buchan I, Matteson E L, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.  JAMA. 2006;  295 2275-2285
    Search in Google Scholar
  • 9 Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.  Ann Rheum Dis. 2006;  65 316-320
    Search in Google Scholar
  • 10 Breedveld F C, Agarwal S, Yin M, Ng C, Li N F, Shaw T. et al . Relationship between clinical response, rituximab pharmacokinetics and peripheral B cell levels in rheumatoid arthritis.  Ann Rheum Dis. 2006;  (Suppl II) 65 179
    Search in Google Scholar
  • 11 Cohen S B, Greenwald M, Dougados M R, Emery P, Furie R, Shaw T M. et al . Efficacy and Safety of Rituximab in Active R A Patients who Experienced an Inadequate Response to one or More Anti- T N F a Therapies ( R E F L E X Study).  American College of Rheumatology Annual Scientific Meeting. 2005;  Abstract #1830
    Search in Google Scholar
  • 12 Dörner T, Kaufmann J, Wegener W A, Teoh N, Goldenberg D M, Burmester G R. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapyof systemic lupus erythematosus.  Arthritis Res Ther. 2006;  (in press)
    Search in Google Scholar
  • 13 Edwards J C, Leandro M J, Cambridge G. Repeated B Lymphocyte Depletion Therapy in Rheumatoid Arthritis: 5 Year Follow-Up.  American College of Rheumatology Annual Scientific Meeting. 2005;  Abstract #270
    Search in Google Scholar
  • 14 Edwards J C, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D R. et al . Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.  N Engl J Med. 2004;  350 2572-2581
    Search in Google Scholar
  • 15 Fleischmann R F, Racewicz J A, Schechtman J, Khraishi M M, Ferraccioli G F, Hessey E. et al . Rituximab efficacy in rheumatoid arthritis is independent of coadministration of glucocorticoids: Results from the Dose-ranging Assessment International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Study.  American College of Rheumatology Annual Scientific Meeting. 2005;  Abstract #263
    Search in Google Scholar
  • 16 Furst D E, Breedveld F C, Kalden J R, Smolen J S, Burmester G R, Bijlsma J W. et al . Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.  Ann Rheum Dis. 2005;  (Suppl 4) 64 2-14
    Search in Google Scholar
  • 17 Genentech .Rituxan Prescribing Information. http://www.gene.com/gene/products/information/immunological/rituxan/insert.jsp 2006
    Search in Google Scholar
  • 18 Genovese M C, Becker J C, Schiff M, Luggen M, Sherrer Y, Kremer J. et al . Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.  N Engl J Med. 2005;  353 1114-1123
    Search in Google Scholar
  • 19 Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A. et al . Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.  Arthritis Rheum. 2005;  52 548-553
    Search in Google Scholar
  • 20 Gladman D D. Psoriatic arthritis.  Dermatol Ther. 2004;  17 350-363
    Search in Google Scholar
  • 21 G oekoop-Ruiterman Y P, Vries-Bouwstra J K, Allaart C F, van Zeben D, Kerstens P J, Hazes J M. et al . Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.  Arthritis Rheum. 2005;  52 3381-3390
    Search in Google Scholar
  • 22 Haibel H, Rudwaleit M, Brandt H C, Grozdanovic Z, Listing J, Kupper H. et al . Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.  Arthritis Rheum. 2006;  54 678-681
    Search in Google Scholar
  • 23 Hoffman G S, Cid M C, Weyand C M, Stone J H, Rendt K E, Salvarani C. et al . Phase II Study of the Safety and Efficacy of Infliximab in Giant Cell Arteritis (GCA):22 Week Interim Analysis.  American College of Rheumatology Annual Scientific Meeting. 2005;  Abstract #663
    Search in Google Scholar
  • 24 Isenberg D A. B cell targeted therapies in autoimmune diseases.  J Rheumatol Suppl. 2006;  77 24-28
    Search in Google Scholar
  • 25 Kavanaugh A, Krueger G G, De Vlam K, Birbara C, Beutler A, Guzzo C. et al . Infliximab Significantly Improves Joint and Skin Involvement in Psoriatic Arthritis to a Substantial Extent and Irrespective of Baseline Joint Involvement or MTX Use: Analysis of Clinical Response from the IMPACT2 Trial.  American College of Rheumatology Annual Scientific Meeting. 2004;  Abstract#1637
    Search in Google Scholar
  • 26 Keogh K A, Ytterberg S R, Fervenza F C, Carlson K A, Schroeder D R, Specks U. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial.  Am J Respir Crit Care Med. 2006;  173 180-187
    Search in Google Scholar
  • 27 Kimby E. Tolerability and safety of rituximab (MabThera).  Cancer Treat Rev. 2005;  31 456-473
    Search in Google Scholar
  • 28 Kremer J M, Dougados M, Emery P, Durez P, Sibilia J, Shergy W. et al . Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.  Arthritis Rheum. 2005;  52 2263-2271
    Search in Google Scholar
  • 29 Kremer J M, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S. et al . Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.  N Engl J Med. 2003;  349 1907-1915
    Search in Google Scholar
  • 30 Landewé R, van der Heijde D M, van Vollenhoven R, Fatenejad S, Klareskog L. A Disconnect between Inflammation and Radiographic Progression in Patients Treated with Etanercept Plus Methotrexate and Etanercept Alone as Compared to Methotrexate Alone: Results from the Tempo-Trial.  American College of Rheumatology Annual Scientific Meeting. 2005;  Abstract #867
    Search in Google Scholar
  • 31 Landewe R B, Boers M, Verhoeven A C, Westhovens R, van de Laar M A, Markusse H M. et al . COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.  Arthritis Rheum. 2002;  46 347-356
    Search in Google Scholar
  • 32 Leandro M J, Cambridge G, Ehrenstein M R, Edwards J C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.  Arthritis Rheum. 2006;  54 613-620
    Search in Google Scholar
  • 33 Leandro M J, Edwards J C, Cambridge G, Ehrenstein M R, Isenberg D A. An open study of B lymphocyte depletion in systemic lupus erythematosus.  Arthritis Rheum. 2002;  46 2673-2677
    Search in Google Scholar
  • 34 Levine T D. Rituximab in the treatment of dermatomyositis: an open-label pilot study.  Arthritis Rheum. 2005;  52 601-607
    Search in Google Scholar
  • 35 Maini R N, Taylor P C, Pavelka K, Emery P, Szechinski J, Balint G. et al . Efficacy of IL-6 Receptor Antagonist MRA in Rheumatoid Arthritis Patients with an Incomplete Response to Methotrexate (CHARISMA).  American College of Rheumatology Annual Scientific Meeting. 2003;  Abstract#1704
    Search in Google Scholar
  • 36 Maksymowych W P, Rahman P, Keystone E, Wong R, Inman R. Efficacy of Adalimumab in Active Ankylosing Spondylitis (AS)-Results of the Canadian AS Study.  American College of Rheumatology Annual Scientific Meeting. 2005;  Abstract #505
    Search in Google Scholar
  • 37 Märker-Hermann E, Zink A. Stellungnahme der Deutschen Gesellschaft für Rheumatologie (DGRh) zum Artikel Bongartz et al: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies.  JAMA. 2006;  295 2275-2285 , 
    http://www.dgrh.de 2006.
    Search in Google Scholar
  • 38 Mease P J, Antoni C E. Psoriatic arthritis treatment: biological response modifiers.  Ann Rheum Dis. 2005;  (Suppl 2) 64 ii78-ii82
    Search in Google Scholar
  • 39 Mease P J, Gladman D D, Keystone E C. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study.  Arthritis Rheum. 2006;  54 1638-1645
    Search in Google Scholar
  • 40 Mease P J, Gladman D D, Ritchlin C T, Ruderman E M, Steinfeld S D, Choy E H. et al . Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.  Arthritis Rheum. 2005;  52 3279-3289
    Search in Google Scholar
  • 41 Mease P J, Goffe B S, Metz J, VanderStoep A, Finck B, Burge D J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.  Lancet. 2000;  356 385-390
    Search in Google Scholar
  • 42 Mease P J, Kivitz A J, Burch F X, Siegel E L, Cohen S B, Ory P. et al . Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.  Arthritis Rheum. 2004;  50 2264-2272
    Search in Google Scholar
  • 43 Molenaar E T, Voskuyl A E, Dinant H J, Bezemer P D, Boers M, Dijkmans B A. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission.  Arthritis Rheum. 2004;  50 36-42
    Search in Google Scholar
  • 44 Ng K P, Leandro M J, Edwards J C, Ehrenstein M R, Cambridge G, Isenberg D A. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus.  Ann Rheum Dis. 2006;  65 942-945
    Search in Google Scholar
  • 45 Nishimoto N. Interleukin-6 in rheumatoid arthritis.  Curr Opin Rheumatol. 2006;  18 277-281
    Search in Google Scholar
  • 46 Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T. et al . Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.  Arthritis Rheum. 2004;  50 1761-1769
    Search in Google Scholar
  • 47 Orencia .Orencia Prescribing Information. http://www.orencia.com/ 2006
    Search in Google Scholar
  • 48 Pando J A, Duray P, Yarboro C, Gourley M F, Klippel J H, Schumacher H R. Synovitis occurs in some clinically normal and asymptomatic joints in patients with early arthritis.  J Rheumatol. 2000;  27 1848-1854
    Search in Google Scholar
  • 49 Rantapaa-Dahlqvist S, de Jong B A, Berglin E, Hallmans G, Wadell G, Stenlund H. et al . Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.  Arthritis Rheum. 2003;  48 2741-2749
    Search in Google Scholar
  • 50 Reiff A. The use of anakinra in juvenile arthritis.  Curr Rheumatol Rep. 2005;  7 434-440
    Search in Google Scholar
  • 51 Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.  Ann Rheum Dis. 2004;  63 665-670
    Search in Google Scholar
  • 52 Salvarani C, Manzini C, Paolazzi G, Trotta A, Manganelli P, Cimmino M. et al . Infliximab in the Treatment of Polymyalgia Rheumatica: A Double Blind, Randomized, Placebo Controlled Study.  American College of Rheumatology Annual Scientific Meeting. 2005;  Abstract #1828
    Search in Google Scholar
  • 53 Sieper J, Rudwaleit M. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?.  Ann Rheum Dis. 2005;  (Suppl 4) 64 iv61-iv64
    Search in Google Scholar
  • 54 Steinfeld S, Pradier O, Song I, Burmester G, Wegener W A, Xu L. et al . Epratuzumab (Anti-CD22 ) for the Treatment of Primary SjöGren’s Syndrome.  American College of Rheumatology Annual Scientific Meeting. 2005;  Abstract #681
    Search in Google Scholar
  • 55 Thatayatikom A, White A J. Rituximab: a promising therapy in systemic lupus erythematosus.  Autoimmun Rev. 2006;  5 18-24
    Search in Google Scholar
  • 56 Van Der Kooij S M, De Vries-Bouwstra J K, Goekoop-Ruiterman Y PM, van Zeben D, Kerstens P J, Peeters A J. et al . What treatment strategy should be chosen after initial failure on methotrexate 25 mg in early rheumatoid arthritis? Data from the BeSt Study.  American College of Rheumatology Annual Scientific Meeting. 2005;  Abstract #1865
    Search in Google Scholar
  • 57 van der Heijde D, Kivitz A, Schiff M H, Sieper J, Dijkmans B A, Braun J. et al . Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.  Arthritis Rheum. 2006;  54 2136-2146
    Search in Google Scholar
  • 58 van Vollenhoven R F, Ernestam S, Cöster L, Dackhammer C, Geborek P, Hellström H. et al . Methotrexate monotherapy is adequate in 30 % of patients with early RA - First Report from the SWEFOT Multicenter Clinical Trial.  American College of Rheumatology Annual Scientific Meeting. 2005;  Abstract #1860
    Search in Google Scholar
  • 59 van Vollenhoven R F, Schechtman J, Szczepanski L, Fleischmann R F, Hazleman B L, Nash P T. et al . Safety and Tolerability of Rituximab in Patients with Moderate to Severe Rheumatoid Arthritis: Results from the Dose-Ranging Assessment International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) study.  American College of Rheumatology Annual Scientific Meeting. 2005;  Abstract #1922
    Search in Google Scholar
  • 60 Wakefield R J, Green M J, Marzo-Ortega H, Conaghan P G, Gibbon W W, McGonagle D. et al . Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease.  Ann Rheum Dis. 2004;  63 382-385
    Search in Google Scholar
  • 61 WGERT Study Group . Etanercept plus standard therapy for Wegener’s granulomatosis.  N Engl J Med. 2005;  352 351-361
    Search in Google Scholar
  • 62 Woo P, Wilkinson N, Prieur A M, Southwood T, Leone V, Livermore P. et al . Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement.  Arthritis Res Ther. 2005;  7 R1281-R1288
    Search in Google Scholar
  • 63 Van Dongen H, Van Aken J, Lard L R, Ronday H K, Speyer I, Westedt M L, Allaart C F, Toes R EM, Breedveld F C, Huizinga T WJ. Probable Rheumatoid Arthritis Methotrexate Versus Placebo Therapy (PROMPT)-Study: Indications For a Window of Opportunity In The Treatment of Patients With Undifferentiated Arthritis.  Ann Rheum Dis. 2006;  65 (Suppl II) 54
    Search in Google Scholar
  • 64 Quinn M A, Conaghan P G, O’Connor P J, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.   Arthritis Rheum. 2005;  52 27-35
    Search in Google Scholar

Dr. Hans Ulrich Scherer

Klinik für Rheumatologie und klinische Immunologie Charité - Universitätsmedizin Berlin

Charitéplatz 1

10117 Berlin

Phone: 030/450613297

Fax: 030/450513986

Email: ulrich.scherer@charite.de